Status:

NO_LONGER_AVAILABLE

Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

Lead Sponsor:

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Conditions:

Primary Hyperoxaluria Type 1 (PH1)

Eligibility:

All Genders

2+ years

Brief Summary

The purpose of this program is to provide participants with access to an investigational drug, nedosiran, for treatment of primary hyperoxaluria type 1 (PH1). Eligible participants may receive nedosir...

Eligibility Criteria

Inclusion

  • Early Access Eligibility Criteria:
  • Written, signed, and dated informed patient/parent consent; and for patients who were minors, age-appropriate assent (performed according to local regulations)
  • Male or female patients at least 2 years of age
  • Genetically-confirmed diagnosis of PH1
  • Accessible for treatment and follow-up and be able to comply with treatment monitoring requirements
  • Not eligible for an ongoing RNAi therapy trial and not participating simultaneously in any interventional clinical research study
  • Patients with PH1 that are not satisfactorily treated with current standard of care; i.e., 24-hour urinary oxalate (Uox) excretion ≥ 0.7 (millimoles) mmol for participants 18 years and older, or greater or lesser than (≥) 0.7 mmol per 1.73 metre square (m\^2) body surface area (BSA) for participants less than 18 years of age
  • Estimated GFR at screening ≥ 30 millilitres per minute (mL/min) normalized to 1.73 m\^2 BSA
  • No renal or hepatic transplantation; prior or planned within the treatment period
  • No documented evidence of clinical manifestations of systemic oxalosis (including pre existing retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations)
  • Patient not currently on dialysis
  • Plasma oxalate ≤ 30 micromoles per litre (μmol/L)
  • Female patients not breastfeeding or pregnant
  • The potential benefit for the individual patient justifies the potential risks of treatment as per prescribing physician judgment

Exclusion

    Key Trial Info

    Start Date :

    Trial Type :

    EXPANDED_ACCESS

    End Date :

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT05993416

    Last Update

    July 22 2025

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.